Is MTVA or ATYR more profitable?

aTyr Pharma's return on equity of -100.14% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% aTyr Pharma N/A -100.14% -73.55%

Does the media refer more to MTVA or ATYR?

In the previous week, MetaVia had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.61 beat MetaVia's score of 0.29 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MGX or MTVA more profitable?

MetaVia has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -51.23% -36.62% MetaVia N/A -172.92% -89.39%

Does the media prefer MGX or MTVA?

In the previous week, MetaVia had 1 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for Metagenomi. MetaVia's average media sentiment score of 0.29 beat Metagenomi's score of 0.22 indicating that MetaVia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, MTVA or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$5.19 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is MTVA or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Estrella Immunopharma N/A N/A -397.36%

Does the media prefer MTVA or ESLA?

In the previous week, MetaVia had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 5 mentions for MetaVia and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.94 beat MetaVia's score of 0.29 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MTVA or GNTA?

MetaVia currently has a consensus price target of $20.00, indicating a potential upside of 966.67%. Given MetaVia's stronger consensus rating and higher possible upside, research analysts plainly believe MetaVia is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, MTVA or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$5.19 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is MTVA or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Genenta Science N/A N/A N/A

Which has higher earnings and valuation, MTVA or ACTU?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$5.19 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is MTVA or ACTU more profitable?

MetaVia's return on equity of -172.92% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Actuate Therapeutics N/A -430.93% -180.86%

Does the media refer more to MTVA or ACTU?

In the previous week, MetaVia had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 5 mentions for MetaVia and 3 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.62 beat MetaVia's score of 0.29 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MetaVia (MTVA) Competitors

$1.88 -0.14 (-6.72%)

As of 09:53 AM Eastern

Compare

MTVA vs. ATYR, MGX, ESLA, GNTA, and ACTU

Should you buy MetaVia stock or one of its competitors? MarketBeat compares MetaVia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MetaVia include aTyr Pharma (ATYR), Metagenomi (MGX), Estrella Immunopharma (ESLA), Genenta Science (GNTA), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.

How does MetaVia compare to aTyr Pharma?

MetaVia (NASDAQ:MTVA) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

MetaVia currently has a consensus target price of $20.00, suggesting a potential upside of 966.67%. aTyr Pharma has a consensus target price of $21.00, suggesting a potential upside of 4,505.26%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 0.6% of MetaVia shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MetaVia has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

MetaVia has higher earnings, but lower revenue than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
aTyr Pharma	$190K	235.32	-$74.12M	-$0.73	N/A

aTyr Pharma's return on equity of -100.14% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
aTyr Pharma	N/A	-100.14%	-73.55%

In the previous week, MetaVia had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.61 beat MetaVia's score of 0.29 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

aTyr Pharma beats MetaVia on 10 of the 14 factors compared between the two stocks.

How does MetaVia compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Metagenomi presently has a consensus target price of $9.00, suggesting a potential upside of 622.89%. MetaVia has a consensus target price of $20.00, suggesting a potential upside of 966.67%. Given MetaVia's higher probable upside, analysts plainly believe MetaVia is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MetaVia has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
MetaVia	N/A	-172.92%	-89.39%

1.4% of MetaVia shares are held by institutional investors. 12.5% of Metagenomi shares are held by company insiders. Comparatively, 0.6% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, MetaVia had 1 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for Metagenomi. MetaVia's average media sentiment score of 0.29 beat Metagenomi's score of 0.22 indicating that MetaVia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MetaVia has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.86	-$87.87M	-$2.30	N/A
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A

Metagenomi has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Summary

Metagenomi and MetaVia tied by winning 8 of the 16 factors compared between the two stocks.

How does MetaVia compare to Estrella Immunopharma?

MetaVia (NASDAQ:MTVA) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

MetaVia presently has a consensus target price of $20.00, indicating a potential upside of 966.67%. Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 651.17%. Given MetaVia's higher probable upside, equities research analysts clearly believe MetaVia is more favorable than Estrella Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.4% of MetaVia shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 0.6% of MetaVia shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Estrella Immunopharma's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Estrella Immunopharma	N/A	N/A	-397.36%

In the previous week, MetaVia had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 5 mentions for MetaVia and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.94 beat MetaVia's score of 0.29 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

MetaVia has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Summary

MetaVia beats Estrella Immunopharma on 7 of the 11 factors compared between the two stocks.

How does MetaVia compare to Genenta Science?

MetaVia (NASDAQ:MTVA) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

MetaVia has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 0.6% of MetaVia shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

MetaVia currently has a consensus price target of $20.00, indicating a potential upside of 966.67%. Given MetaVia's stronger consensus rating and higher possible upside, research analysts plainly believe MetaVia is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genenta Science's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Genenta Science	N/A	N/A	N/A

In the previous week, MetaVia had 3 more articles in the media than Genenta Science. MarketBeat recorded 5 mentions for MetaVia and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.43 beat MetaVia's score of 0.29 indicating that Genenta Science is being referred to more favorably in the news media.

Company	Overall Sentiment
MetaVia	Neutral
Genenta Science	Neutral

Summary

Genenta Science beats MetaVia on 6 of the 11 factors compared between the two stocks.

How does MetaVia compare to Actuate Therapeutics?

MetaVia (NASDAQ:MTVA) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 966.67%. Actuate Therapeutics has a consensus price target of $17.50, indicating a potential upside of 775.00%. Given MetaVia's higher probable upside, equities analysts clearly believe MetaVia is more favorable than Actuate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, MetaVia had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 5 mentions for MetaVia and 3 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.62 beat MetaVia's score of 0.29 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MetaVia's return on equity of -172.92% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Actuate Therapeutics	N/A	-430.93%	-180.86%

1.4% of MetaVia shares are owned by institutional investors. 0.6% of MetaVia shares are owned by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MetaVia has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Summary

MetaVia beats Actuate Therapeutics on 8 of the 13 factors compared between the two stocks.

Get MetaVia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTVA vs. The Competition

Export

Metric	MetaVia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.63M	$3.29B	$6.46B	$11.73B
Dividend Yield	N/A	2.33%	2.67%	5.56%
P/E Ratio	-0.36	19.62	24.17	24.35
Price / Sales	N/A	300.46	534.05	122.29
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	0.81	8.21	10.56	6.82
Net Income	-$12.97M	$23.89M	$3.56B	$337.41M
7 Day Performance	-27.04%	1.11%	0.22%	2.49%
1 Month Performance	93.30%	-0.74%	0.66%	3.69%
1 Year Performance	-77.27%	40.35%	22.16%	27.72%

MetaVia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTVA MetaVia	2.2807 of 5 stars	$1.88 -6.7%	$20.00 +966.7%	-75.7%	$9.63M	N/A	N/A	8	Short Interest Increase Gap Down
ATYR aTyr Pharma	3.7209 of 5 stars	$0.53 +5.0%	$21.00 +3,900.0%	-91.2%	$51.38M	$190K	N/A	53
MGX Metagenomi	3.0806 of 5 stars	$1.36 +1.9%	$9.00 +564.2%	-16.1%	$51.02M	$25.21M	N/A	236
ESLA Estrella Immunopharma	3.0387 of 5 stars	$1.15 +10.1%	$8.00 +598.7%	+5.6%	$49.27M	N/A	N/A	N/A
GNTA Genenta Science	0.4624 of 5 stars	$2.05 -2.8%	N/A	-49.7%	$48.36M	N/A	N/A	7	Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTVA) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetaVia (MTVA) Competitors

MTVA vs. ATYR, MGX, ESLA, GNTA, and ACTU

How does MetaVia compare to aTyr Pharma?

Summary

How does MetaVia compare to Metagenomi?

Summary

How does MetaVia compare to Estrella Immunopharma?

Summary

How does MetaVia compare to Genenta Science?

Summary

How does MetaVia compare to Actuate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MetaVia (MTVA) Competitors

MTVA vs. ATYR, MGX, ESLA, GNTA, and ACTU

How does MetaVia compare to aTyr Pharma?

Do analysts rate MTVA or ATYR?

Do insiders and institutionals have more ownership in MTVA or ATYR?

Which has more volatility and risk, MTVA or ATYR?

Which has preferable earnings and valuation, MTVA or ATYR?

Is MTVA or ATYR more profitable?

Does the media refer more to MTVA or ATYR?

Summary

How does MetaVia compare to Metagenomi?

Do analysts recommend MGX or MTVA?

Is MGX or MTVA more profitable?

Do institutionals and insiders have more ownership in MGX or MTVA?

Does the media prefer MGX or MTVA?

Which has preferable earnings and valuation, MGX or MTVA?

Which has more volatility & risk, MGX or MTVA?

Summary

How does MetaVia compare to Estrella Immunopharma?

Do analysts rate MTVA or ESLA?

Do institutionals & insiders hold more shares of MTVA or ESLA?

Is MTVA or ESLA more profitable?

Does the media prefer MTVA or ESLA?

Which has stronger earnings & valuation, MTVA or ESLA?

Which has more volatility & risk, MTVA or ESLA?

Summary

How does MetaVia compare to Genenta Science?

Which has more risk and volatility, MTVA or GNTA?

Do institutionals & insiders believe in MTVA or GNTA?

Which has higher earnings and valuation, MTVA or GNTA?

Do analysts recommend MTVA or GNTA?

Is MTVA or GNTA more profitable?

Does the media prefer MTVA or GNTA?

Summary

How does MetaVia compare to Actuate Therapeutics?

Do analysts recommend MTVA or ACTU?

Does the media refer more to MTVA or ACTU?

Is MTVA or ACTU more profitable?

Do institutionals and insiders believe in MTVA or ACTU?

Which has more volatility & risk, MTVA or ACTU?

Which has higher earnings and valuation, MTVA or ACTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools